I dont think anyone wants to pursue a weight loss option that, despite providing short-term results, will eventually cause you to gain back all their weight (and then some)
Rather than targeting more receptors with a single molecule, it combines two separate compounds, cagrilintide (an amylin analogue) and semaglutide (a GLP-1 agonist), into a single weekly injection
You see an actual physician in person, your plan is built around your individual health and history rather than a standardized track, and the same team manages your medication, your protein and muscle, your side effects, and your long-term maintenance over time
market before the anticipated 2032 patent expiration (per Novo Nordisks 2023 annual report) has investors and industry watchers buzzing, as it could lower costs for patients and disrupt Novo Nordisks market dominance
However, the right medication depends on your medical history, laboratory results, health goals, and your physician's recommendation